{"id":95139,"date":"2024-05-07T09:03:00","date_gmt":"2024-05-07T07:03:00","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/?p=95139"},"modified":"2024-05-08T14:50:37","modified_gmt":"2024-05-08T12:50:37","slug":"first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/","title":{"rendered":"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia"},"content":{"rendered":"<p><strong>The biotechnology company<a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/onechain-immunotherapeutics-s-l\/\" target=\"_blank\" rel=\"noopener\"> OneChain Immunotherapeutics<\/a>, based in the Barcelona Science Park and specializing in the development of CAR T cell therapies for oncological diseases, announced today the first patient dosed in the CARxALL clinical trial, a study evaluating its most advanced product, OC-1, in patients with cortical T-cell acute lymphoblastic leukemia (coT-ALL). The trial, open to pediatric and adult patients worldwide, is being conducted in Barcelona at Hospital Cl\u00ednic and Hospital Sant Joan de D\u00e9u.<\/strong><\/p>\n<p>The CARxALL study (ClinicalTrials.gov identifier NCT05679895), led by <strong>Dr. N\u00faria Mart\u00ednez <\/strong>and <strong>Dr. Susana Rives<\/strong>, is a dose-escalation trial, aiming to evaluate for the first time in humans the safety and tolerability of a CAR T therapy (OC-1) in patients with coT-ALL, a subtype of leukemia that accounts for 20% of T-cell leukemias and is characterized by a poor prognosis in those patients who do not respond to existing therapies. \u00a0The first patient treated at Hospital Cl\u00ednic, a young man who had previously undergone several treatment lines without success, has received the full dose with no major issue.<\/p>\n<p>\u201cThis treatment offers hope for patients who have exhausted all available options\u201d, explains <strong>Dr. Nuria Martinez<\/strong>, principal investigator at Hospital Cl\u00ednic. It is essential that we do everything we can to ensure that as many patients as possible can access these innovative therapies. We are very grateful to OneChain for all their support with the clinical trial and hope to stablish a long-lasting relation with them. Their pipeline has a lot to offer to patients and families\u201d.<\/p>\n<p>CAR T therapies are a type of immunotherapy that involves the genetic modification of immune cells called T-cells in the laboratory, to enhance and target their ability to recognize and attack cancer cells. This strategy has already shown promising results in other forms of leukemia and lymphoma. However, applying these therapies to T-cell leukemias such as coT-ALL presents significant challenges because tumor and healthy T cells exhibit almost the same molecules on their surface. As a result, competing CAR T therapies aimed at T-ALL destroy both type of cells, potentially leading to severe immunosuppression in patients.<\/p>\n<p>OC-1, the product being evaluated in the trial, aims to overcome these obstacles by targeting CD1a, a specific protein found almost exclusively in the tumor cells of patients with coT-ALL. \u201cOur laboratory was the first to develop and validate a CAR T specific to this therapeutic target\u201d, says <strong>Dr. Pablo Men\u00e9ndez<\/strong>, founder of OCI and director of the stem cell biology, developmental leukemia, and immunotherapy group at the Josep Carreras Leukemia Research Institute (IJC<strong>). <\/strong>\u201cSeeing now how academic work reaches patients is a dream come true for all of us\u201d.<\/p>\n<p>This is an important milestone and a very proud moment for OneChain and all our partners,&#8221; said<strong> Dr. Stefanos Theoharis,<\/strong> CEO of the company. &#8220;Their unending support and commitment to our company and the patients has finally come to bear fruit. My heartfelt thanks go to all those individuals and organizations who have helped us achieve this milestone, including the joint effort of the IJC, the OneChain team, the staff at Hospital Cl\u00ednic and Hospital Sant Joan de D\u00e9u, the Josep Carreras Foundation, our main investor, Invivo Partners, the Unoentrecienmil Foundation, the Banc de Sang I Teixits (BST), and the CDTI Innvierte program.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The biotechnology company OneChain Immunotherapeutics, based in the Barcelona Science Park and specializing in the development of CAR T cell therapies for oncological diseases, announced today the first patient dosed&#8230;<\/p>\n","protected":false},"author":11,"featured_media":95134,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-95139","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"The biotechnology company OneChain Immunotherapeutics, based in the Barcelona Science Park and specializing in the development of CAR T cell therapies for oncological diseases, announced today the first patient dosed...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-07T07:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-08T12:50:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/onechain-team.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Iuris\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Iuris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/\"},\"author\":{\"name\":\"Iuris\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/2cac99ef7339e3499496b54bb2e12e7d\"},\"headline\":\"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia\",\"datePublished\":\"2024-05-07T07:03:00+00:00\",\"dateModified\":\"2024-05-08T12:50:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/\"},\"wordCount\":563,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/onechain-team.jpg\",\"articleSection\":[\"COMPANIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/\",\"name\":\"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/onechain-team.jpg\",\"datePublished\":\"2024-05-07T07:03:00+00:00\",\"dateModified\":\"2024-05-08T12:50:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/2cac99ef7339e3499496b54bb2e12e7d\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/onechain-team.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/onechain-team.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/2cac99ef7339e3499496b54bb2e12e7d\",\"name\":\"Iuris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"caption\":\"Iuris\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminiuris\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/","og_locale":"en_US","og_type":"article","og_title":"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia - Parc Cient\u00edfic de Barcelona","og_description":"The biotechnology company OneChain Immunotherapeutics, based in the Barcelona Science Park and specializing in the development of CAR T cell therapies for oncological diseases, announced today the first patient dosed...","og_url":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2024-05-07T07:03:00+00:00","article_modified_time":"2024-05-08T12:50:37+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/onechain-team.jpg","type":"image\/jpeg"}],"author":"Iuris","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Iuris","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/"},"author":{"name":"Iuris","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d"},"headline":"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia","datePublished":"2024-05-07T07:03:00+00:00","dateModified":"2024-05-08T12:50:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/"},"wordCount":563,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/onechain-team.jpg","articleSection":["COMPANIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/","url":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/","name":"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/onechain-team.jpg","datePublished":"2024-05-07T07:03:00+00:00","dateModified":"2024-05-08T12:50:37+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/onechain-team.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/onechain-team.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/first-patient-treated-in-onechain-immunotherapeutics-car-t-trial-for-cortical-t-cell-acute-lymphoblastic-leukemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"First patient treated in OneChain\u2019 CAR T trial for cortical T-cell acute lymphoblastic leukemia"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d","name":"Iuris","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","caption":"Iuris"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminiuris\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/95139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=95139"}],"version-history":[{"count":4,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/95139\/revisions"}],"predecessor-version":[{"id":95260,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/95139\/revisions\/95260"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/95134"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=95139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=95139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=95139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}